en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">To evaluate the value of six tumor markers including squamous cell carcinoma antigen (SCCA), cytokeratin 19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), glycoconjugate antigen 125 (CA125), neuron-specific enolase (NSE), along with gastrin-releasing peptide precursor (ProGRP) in the diagnosis and pathological staging of lung cancer (LC) alone or in combination. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Methods: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">A retrospective analysis was performed on 300 patients of which 62 cases were diagnosed as small cell lung cancer (SCLC), 105 adenocarcinoma (LUAD), 41 squamous cell carcinoma (LUSC) and 92 large cell lung cancer (LCLC) by histopathology. Another 364 patients with benign lung disease in the same period were chosen for the benign lung disease group. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">The detection results of 6 tumor markers in serum of LC, SCCA,</span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">NSE and ProGP patients with different pathological types were higher compared with lung benign lesions group (P<0.01). LC can be separated into SCLC along with non-Small cell lung cancer (NSCLC) by NSE+ProGRP combination. The detection rate of lung squamous cell carcinoma by SCCA+ cytokeratin 19 fragment (CYFRA21-1) was higher than that by CEA+CA125 combination for adenocarcinoma. The combined determination of NSE and ProGRP was highly sensitive to SCLC. In NSCLC, the combined detection of SCC-Ag and CYFRA21-1 showed high sensitivity to LUSC. CEA+CA125 combined detection was highly sensitive to LUAD. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">The combined determination of NSE and ProGRP was highly sensitive to SCLC. CEA+CA125 combined detection was highly sensitive to LUAD, and SCCA+CYFR21-1+CEA+CA125 was the best combined detection analysis of multiple indexes.</span></span></span></span></span></span></span></span></span></div> Squamous cell carcinoma antigen, CYFRA21-1, carcinoembryonic antigen, lung cancer. 283 287 http://ijrr.com/browse.php?a_code=A-10-1-1171&slc_lang=en&sid=1 RM. Zhou 7900319475328460026767 7900319475328460026767 No Department of Respiratory and Critical Care Medicine, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, China ZH. Cai 7900319475328460026768 7900319475328460026768 No Department of Respiratory and Critical Care Medicine, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, China YR. Yuan 7900319475328460026769 7900319475328460026769 No Department of Respiratory and Critical Care Medicine, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, China ZL. Zhou 7900319475328460026770 7900319475328460026770 No Department of Respiratory and Critical Care Medicine, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, China H. Ding 7900319475328460026771 7900319475328460026771 No Department of Respiratory and Critical Care Medicine, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, China YQ. Cheng 7900319475328460026772 7900319475328460026772 No Department of Respiratory and Critical Care Medicine, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, China L. Liang gyliangli@outlook.com 7900319475328460026773 7900319475328460026773 Yes Department of Respiratory and Critical Care Medicine, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, China ZN. Tuo tuozineng888@163.com 7900319475328460026774 7900319475328460026774 No Department of Respiratory and Critical Care Medicine, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, China